These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 27756479

  • 1. Usefulness of Iron Deficiency Correction in Management of Patients With Heart Failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry].
    Wienbergen H, Pfister O, Hochadel M, Michel S, Bruder O, Remppis BA, Maeder MT, Strasser R, von Scheidt W, Pauschinger M, Senges J, Hambrecht R, RAID-HF (Registry Analysis of Iron Deficiency–Heart Failure) REGISTRY Study Group.
    Am J Cardiol; 2016 Dec 15; 118(12):1875-1880. PubMed ID: 27756479
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study.
    Wienbergen H, Pfister O, Hochadel M, Fach A, Backhaus T, Bruder O, Remppis BA, Maeder MT, von Scheidt W, Pauschinger M, Senges J, Hambrecht R, RAID-HF (Registry Analysis of Iron Deficiency-Heart Failure) Study Group.
    Clin Res Cardiol; 2019 Jan 15; 108(1):93-100. PubMed ID: 30003365
    [Abstract] [Full Text] [Related]

  • 3. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
    Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, Rosano GMC, Jankowska EA, Anker SD, Lund LH, Savarese G.
    Eur J Heart Fail; 2021 Nov 15; 23(11):1844-1854. PubMed ID: 34476878
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
    Hofmarcher T, Cabrales Alin D, Linde C.
    Scand Cardiovasc J; 2018 Dec 15; 52(6):348-355. PubMed ID: 30457358
    [Abstract] [Full Text] [Related]

  • 5. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
    Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF, HEART-FID Trial Investigators.
    Circ Heart Fail; 2021 May 15; 14(5):e008100. PubMed ID: 34003690
    [Abstract] [Full Text] [Related]

  • 6. Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study.
    Wahid M, Islam S, Sepehrvand N, Dover DC, McAlister FA, Kaul P, Ezekowitz JA.
    Circ Heart Fail; 2024 Apr 15; 17(4):e011351. PubMed ID: 38572652
    [Abstract] [Full Text] [Related]

  • 7. Iron Deficiency Treatment in Patients with Heart Failure.
    Jankowska EA, Drozd M, Ponikowski P.
    Handb Exp Pharmacol; 2017 Apr 15; 243():561-576. PubMed ID: 28405775
    [Abstract] [Full Text] [Related]

  • 8. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P, Kirwan BA, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Khintibidze I, Kragten H, Martinez FA, McDonagh T, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Jankowska EA.
    Eur J Heart Fail; 2019 Dec 15; 21(12):1651-1658. PubMed ID: 31883356
    [Abstract] [Full Text] [Related]

  • 9. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
    Gutzwiller FS, Pfeil AM, Comin-Colet J, Ponikowski P, Filippatos G, Mori C, Braunhofer PG, Szucs TD, Schwenkglenks M, Anker SD.
    Int J Cardiol; 2013 Oct 09; 168(4):3878-83. PubMed ID: 23870642
    [Abstract] [Full Text] [Related]

  • 10. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U.
    Atheroscler Suppl; 2015 May 09; 18():199-208. PubMed ID: 25936327
    [Abstract] [Full Text] [Related]

  • 11. Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy.
    Cases Amenós A, Ojeda López R, Portolés Pérez JM, en representación del Grupo de Anemia de la S.E.N..
    Nefrologia; 2017 May 09; 37(6):587-591. PubMed ID: 28610806
    [Abstract] [Full Text] [Related]

  • 12. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P.
    Eur J Heart Fail; 2018 Jan 09; 20(1):125-133. PubMed ID: 28436136
    [Abstract] [Full Text] [Related]

  • 13. [Is iron important in heart failure?].
    Murín J, Pernický M.
    Vnitr Lek; 2015 Dec 09; 61(12 Suppl 5):5S50-5. PubMed ID: 27124973
    [Abstract] [Full Text] [Related]

  • 14. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators.
    N Engl J Med; 2009 Dec 17; 361(25):2436-48. PubMed ID: 19920054
    [Abstract] [Full Text] [Related]

  • 15. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 16. Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions.
    Cunha GJL, Rocha BML, Menezes Falcão L.
    Eur J Intern Med; 2018 Jun 23; 52():1-7. PubMed ID: 29680173
    [Abstract] [Full Text] [Related]

  • 17. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R, Ternavasio-de la Vega HG, Moralejo Alonso L, Inés Revuelta S, Fuertes Martín A.
    Med Clin (Barc); 2015 Aug 07; 145(3):108-11. PubMed ID: 25579771
    [Abstract] [Full Text] [Related]

  • 18. Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group.
    Pezel T, Audureau E, Mansourati J, Baudry G, Ben Driss A, Durup F, Fertin M, Godreuil C, Jeanneteau J, Kloeckner M, Koukoui F, Kesri-Tartière L, Laperche T, Roubille F, Cohen-Solal A, Damy T.
    ESC Heart Fail; 2021 Apr 07; 8(2):1509-1521. PubMed ID: 33619905
    [Abstract] [Full Text] [Related]

  • 19. [Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond].
    Češka R.
    Vnitr Lek; 2014 Dec 07; 60(12):1033-9. PubMed ID: 25692829
    [Abstract] [Full Text] [Related]

  • 20. Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners.
    Drozd M, Jankowska EA, Banasiak W, Ponikowski P.
    Am J Cardiovasc Drugs; 2017 Jun 07; 17(3):183-201. PubMed ID: 28039585
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.